US2008014271A1
|
|
Novel pharmaceutical compositions comprising levetiracetam
|
GB0625325D0
|
|
A protein involved in cancer
|
GB0625162D0
|
|
Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceuticall compositions thereof
|
GB0625176D0
|
|
Peptides
|
GB0624891D0
|
|
A protein involved in cancer
|
GB0624890D0
|
|
A protein involved in protein
|
CN101356194A
|
|
Antibody molecules having specificity for human IL-6
|
GB0623955D0
|
|
Novel aminothienopyridinone derivatives processes for preparing them and pharmaceutical compositions thereof
|
GB0623599D0
|
|
Bicyclic and heterobicyclic derivatives,processes for preparing them and their uses
|
GB0623615D0
|
|
Bicyclic and heterobicyclic derivatives,processes for preparing them and their uses
|
WO2007060411A1
|
|
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
GB0620818D0
|
|
Therapeutic agents
|
GB0620729D0
|
|
Biological products
|
GB0620059D0
|
|
Therapeutic agents
|
GB0620062D0
|
|
Therapeutic agents
|
GB0619291D0
|
|
Altered antibodies
|
GB0618938D0
|
|
Cyclic amino derivatives
|
GB0617966D0
|
|
Novel 2 amino-pyrimidine derivatives, processes for preparing them, pharmaceutical compositions thereof
|
WO2007031734A1
|
|
Comb polymers
|
GB0616214D0
|
|
Therapeutic Agents
|